Instil Bio Inc (TIL)

$19.40 +0.40 (2.11%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	130.96M
Revenue (ttm)	0.00
Net Income (ttm)	-74.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.64

Volume	39,900
Avg Vol	138,410
Day's Range	N/A - N/A
Shares Out	6.75M
Stochastic %K	38%
Beta	2.07
Analysts	Strong Sell
Price Target	$118.67

Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 499 3350

Website: instilbio.com

Address:

3963 Maple Avenue, Suite 350, Dallas, United States

Magic8BallResponse Oct. 15 at 11:19 PM

$TIL

0 · Reply

Magic8BallResponse Oct. 13 at 2:05 PM

$TIL

0 · Reply

Magic8BallResponse Oct. 9 at 8:01 PM

$TIL

0 · Reply

Magic8BallResponse Oct. 9 at 7:28 PM

$TIL

0 · Reply

BillionerOfKing Oct. 2 at 1:30 PM

$TIL Current Stock Price: $19.15 No options data available.

0 · Reply

360nocondom Sep. 25 at 10:01 PM

$TIL Was hoping to be able to get some profit here as previous trades was excellent. Waited for the bottom after my last 5% loss here (the first loss that broke my streak 😭), but it looks like its not coming anytime soon.

0 · Reply

Magic8BallResponse Sep. 24 at 2:42 PM

$SMMT $TIL ..... Reversal

0 · Reply

Bigmal1 Sep. 24 at 4:31 AM

$DRCT $CHSN $AEHL $TIL Which one to average down in?

1 · Reply

Magic8BallResponse Sep. 23 at 7:42 PM

$TIL Volume....

0 · Reply

Magic8BallResponse Sep. 23 at 1:16 PM

$TIL Back into $ATXS....

0 · Reply

Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Aug 13, 2025, 6:00 AM EDT - 2 months ago

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 31, 2025, 6:00 AM EDT - 3 months ago

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

$Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors$